Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Alternative endogenous protein processing via an autophagy-dependent pathway compensates for Yersinia-mediated inhibition of endosomal major histocompatibility complex class II antigen presentation.

Rüssmann H, Panthel K, Köhn B, Jellbauer S, Winter SE, Garbom S, Wolf-Watz H, Hoffmann S, Grauling-Halama S, Geginat G.

Infect Immun. 2010 Dec;78(12):5138-50. doi: 10.1128/IAI.00155-10. Epub 2010 Sep 27.

2.

Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction.

Rüssmann H, Gerdemann U, Igwe EI, Panthel K, Heesemann J, Garbom S, Wolf-Watz H, Geginat G.

Infect Immun. 2003 Jun;71(6):3463-72.

3.

Yersinia enterocolitica-mediated translocation of defined fusion proteins to the cytosol of mammalian cells results in peptide-specific MHC class I-restricted antigen presentation.

Rüssmann H, Weissmüller A, Geginat G, Igwe EI, Roggenkamp A, Bubert A, Goebel W, Hof H, Heesemann J.

Eur J Immunol. 2000 May;30(5):1375-84.

4.
5.

CCR2+ Inflammatory Dendritic Cells and Translocation of Antigen by Type III Secretion Are Required for the Exceptionally Large CD8+ T Cell Response to the Protective YopE69-77 Epitope during Yersinia Infection.

Zhang Y, Tam JW, Mena P, van der Velden AW, Bliska JB.

PLoS Pathog. 2015 Oct 15;11(10):e1005167. doi: 10.1371/journal.ppat.1005167. eCollection 2015 Oct.

6.

Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins.

Rüssmann H, Igwe EI, Sauer J, Hardt WD, Bubert A, Geginat G.

J Immunol. 2001 Jul 1;167(1):357-65.

7.
8.

Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.

Wiedig CA, Kramer U, Garbom S, Wolf-Watz H, Autenrieth IB.

Vaccine. 2005 Oct 10;23(42):4984-98.

PMID:
15985316
9.
10.

Cell type-specific effects of Yersinia pseudotuberculosis virulence effectors.

Fahlgren A, Westermark L, Akopyan K, Fällman M.

Cell Microbiol. 2009 Dec;11(12):1750-67. doi: 10.1111/j.1462-5822.2009.01365.x. Epub 2009 Aug 4.

PMID:
19681909
11.
12.

A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Zhang Y, Mena P, Romanov G, Lin JS, Smiley ST, Bliska JB.

Infect Immun. 2012 Jan;80(1):206-14. doi: 10.1128/IAI.05971-11. Epub 2011 Nov 7.

14.

The GAP activity of type III effector YopE triggers killing of Yersinia in macrophages.

Wang X, Parashar K, Sitaram A, Bliska JB.

PLoS Pathog. 2014 Aug 28;10(8):e1004346. doi: 10.1371/journal.ppat.1004346. eCollection 2014 Aug.

16.

Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes.

Musson JA, Morton M, Walker N, Harper HM, McNeill HV, Williamson ED, Robinson JH.

J Biol Chem. 2006 Sep 8;281(36):26129-35. Epub 2006 Jul 13.

17.

Innate immune recognition of Yersinia pseudotuberculosis type III secretion.

Auerbuch V, Golenbock DT, Isberg RR.

PLoS Pathog. 2009 Dec;5(12):e1000686. doi: 10.1371/journal.ppat.1000686. Epub 2009 Dec 4.

18.

Regulation of Yersinia Yop-effector delivery by translocated YopE.

Aili M, Isaksson EL, Carlsson SE, Wolf-Watz H, Rosqvist R, Francis MS.

Int J Med Microbiol. 2008 Apr;298(3-4):183-92. Epub 2007 Jun 26.

PMID:
17597003
19.

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.

Dörfel D, Appel S, Grünebach F, Weck MM, Müller MR, Heine A, Brossart P.

Blood. 2005 Apr 15;105(8):3199-205. Epub 2004 Dec 23.

20.

YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infection.

González-Juarbe N, Shen H, Bergman MA, Orihuela CJ, Dube PH.

PLoS One. 2017 Feb 16;12(2):e0172314. doi: 10.1371/journal.pone.0172314. eCollection 2017.

Supplemental Content

Support Center